Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Merck
Mallinckrodt
Dow
Moodys

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,665,772

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,665,772 protect, and when does it expire?

Patent 5,665,772 protects AFINITOR DISPERZ, AFINITOR, and ZORTRESS, and is included in three NDAs.

Protection for AFINITOR DISPERZ has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty patent family members in twenty-six countries.

Summary for Patent: 5,665,772
Title: O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants
Abstract:Novel derivatives of rapamycin, particularly 9-deoxorapamycins, 26-dihydro-rapamycins, and 40-0-substituted and 28,40-0,0-di-substituted rapamycins, are found to have pharmaceutical utility, particularly as an immunosuppressants.
Inventor(s): Cottens; Sylvain (Witterswil, CH), Sedrani; Richard (Basel, CH)
Assignee: Sandoz Ltd. (Basel, CH)
Application Number:08/416,673
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,665,772
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,665,772

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-001 Aug 29, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-002 Aug 29, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis Pharm AFINITOR DISPERZ everolimus TABLET, FOR SUSPENSION;ORAL 203985-003 Aug 29, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-003 Jul 9, 2010 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-001 Mar 30, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-004 Mar 30, 2012 RX Yes No   Start Trial   Start Trial Y   Start Trial
Novartis AFINITOR everolimus TABLET;ORAL 022334-002 Mar 30, 2009 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,665,772

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9221220Oct 09, 1992
PCT Information
PCT FiledSeptember 24, 1993PCT Application Number:PCT/EP93/02604
PCT Publication Date:April 28, 1994PCT Publication Number: WO94/09010

International Family Members for US Patent 5,665,772

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 173736   Start Trial
Austria 272063   Start Trial
Australia 4819293   Start Trial
Australia 676198   Start Trial
Brazil 1100353   Start Trial
Canada 2145383   Start Trial
Canada 2476257   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKinsey
Colorcon
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.